Oral contraceptive usage and the expression of CA 15-3 and c-erbB-2 in the saliva of healthy women

被引:12
作者
McIntyre, R
Bigler, L
Dellinger, T
Pfeifer, M
Mannery, T
Streckfus, C
机构
[1] Univ Mississippi, Med Ctr, Dept Dent Res, Sch Dent, Jackson, MS 39216 USA
[2] Univ Mississippi, Med Ctr, Dept Med, Div Oncol, Jackson, MS 39216 USA
来源
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS | 1999年 / 88卷 / 06期
关键词
D O I
10.1016/S1079-2104(99)70011-9
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective. This study was conducted to determine if oral contraceptive use affected the salivary levels of 2 cancer biomarkers, cancer antigen 15-3 (CA 15-3), and c-erbB-2 (erb) among women. Study design. A total of 40 women were recruited for this study, 20 controls and 20 using oral contraceptives. The average ages were 27.4 years (control) and 27.1 years (using estrogen supplements). Stimulated whole saliva specimens were collected from each woman. CA 15-3 levels were determined using enzyme immunoassay (EIA) while c-erbB-2 levels were determined by standard ELISA methods. Results. Findings from this study indicate that there were no significant differences between the control and study groups. Conclusions. Therefore, saliva may be a useful tool for monitoring women with high estrogen levels due to either tumor load or any treatment regimen, ie, the levels of the cancer biomarkers CA 15-3 and erb are not affected by increased levels of estrogen in the body.
引用
收藏
页码:687 / 690
页数:4
相关论文
共 20 条
[1]  
Bast RC, 1998, J CLIN ONCOL, V16, P793
[2]  
Brinton LA, 1998, MENOPAUSE, V5, P145
[3]   The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer [J].
Fehm, T ;
Maimonis, P ;
Katalinic, A ;
Jäger, WH .
ONCOLOGY, 1998, 55 (01) :33-38
[4]   Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients [J].
Fehm, T ;
Maimonis, P ;
Weitz, S ;
Teramoto, Y ;
Katalinic, A ;
Jager, W .
BREAST CANCER RESEARCH AND TREATMENT, 1997, 43 (01) :87-95
[5]   COMBINED ORAL-CONTRACEPTIVES - DO WE KNOW ALL OF THEIR EFFECTS [J].
HANNAFORD, PC .
CONTRACEPTION, 1995, 51 (06) :325-327
[6]  
Krainer M, 1997, ONCOLOGY, V54, P475
[7]   c-erbB-2 oncoprotein, CEA, and CA15.3 in patients with breast cancer:: prognostic value [J].
Molina, R ;
Jo, J ;
Filella, X ;
Zanon, G ;
Pahisa, J ;
Muñoz, M ;
Farrus, B ;
Latre, ML ;
Escriche, C ;
Estape, J ;
Ballesta, AM .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 51 (02) :109-119
[8]   Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases [J].
Molina, R ;
Jo, J ;
Filella, X ;
Bruix, J ;
Castells, A ;
Hague, M ;
Ballesta, AM .
TUMOR BIOLOGY, 1997, 18 (03) :188-196
[9]  
MURPHY GP, 1998, CA A J CLIN, V48, P6
[10]   A COMPARISON OF WHOLE MOUTH RESTING AND STIMULATED SALIVARY MEASUREMENT PROCEDURES [J].
NAVAZESH, M ;
CHRISTENSEN, CM .
JOURNAL OF DENTAL RESEARCH, 1982, 61 (10) :1158-1162